CL CLX Clorox Загрузка... : Бычьи и медвежьи мнения аналитиков

A news wire reports a broad list of price target increases from multiple analysts across dozens.

Clorox reported fiscal fourth quarter earnings that beat analyst expectations despite lower.

Clorox projects tough fiscal year

Guidance is cautious, assuming continued muted category growth and pervasive value-seeking behavior. The company plans to offset with targeted investments in superiority, but the top-line outlook is flat to slightly positive.

Clorox reports fourth quarter net sales down 2 percent with adjusted EPS down 42 percent amid.

CLX trades at 15.5x P/E and 12.8x EV/EBITDA vs historical averages of 30-45x and 18-24x respectively. Defensive staples with stable cash flow and a 4.7% dividend yield offer a favorable asymmetric risk/reward at current valuation. Re-rating toward historical multiples plus normalized FCF could generate ~200% upside over 4-5 years. Consumer spending weakness, further macro shocks, or prolonged supply chain/restructuring costs could push the stock lower short-term.

Beaten-down consumer staples will eventually rally.

Church and Dwight and Colgate-Palmolive earnings indicate US consumers remain willing to pay.

UBS, Stephens, Jefferies, Exane BNP Paribas, TD Cowen, Morgan Stanley, Wells Fargo.

Goldman Sachs upgrades CIB to Buy, KeyBanc upgrades FLY to Overweight.

Avoid defensive staples like Clorox.

Clorox is dead money

Hidden Valley Ranch sales jumped 20%+ in June 2026, per Clorox, driven by World Cup tourists discovering ranch and TSA-related publicity. This unexpected demand spike for a high-margin consumer product could positively impact Clorox’s next quarterly earnings, especially if momentum continues through summer events. Short-term bullish catalyst from World Cup and 250th anniversary celebrations; potential for continued international expansion via "ranchbassadors" program. The sales bump may be temporary (event-driven); ranch is a mature category; Clorox faces broader headwinds in cleaning/bleach segments; Kraft Heinz competing with TSA-compliant packets.

Buy Clorox for yield and upgrade.

The author notes unusual large moves in megacap staples and pharma stocks but provides no.

Reports CEO resignation for health reasons, a management change with potential strategic.

Clorox reports flat revenue and management is cutting earnings forecasts in an inflationary environment, signaling declining unit sales. Consumer staples usually hold up in inflation, but here the core business is shrinking – a classic profit margin squeeze and volume loss. If the average consumer is pulling back, non-discretionary staples like Clorox can still underperform, making a short/bearish stance sensible while the broader market rallies. Inflation could allow pricing power to offset volume; a geopolitical shift might boost demand for cleaning products; short squeezes on a stable dividend stock.

A +6 upvoted comment highlights CLX (Clorox) at 14 P/E, 5.7% dividend yield, calling it a “boomer stock” to buy low. Defensive, high-dividend stocks tend to outperform in uncertain, rate-cut environments; the value proposition is clear. The community sees CLX as a safe haven with attractive valuation and yield, suitable for a “buy and forget” approach. Consumer staple stocks lag in risk-on rallies; one comment does not constitute broad consensus.

Management's tone is cautious and neutral, acknowledging missed expectations in Q3 due to supply chain costs and delayed savings, while expressing confidence in the long-term path forward with innovation and distribution gains.

Expanding relationship with Clorox suggests deeper integration and potential higher spend with Omnicom for its marketing needs.

Author discloses CLX as a current long position contributing to a 3% daily portfolio gain.

Author discloses a large current long position in CLX as part of a defensive consumer staples.

Long CLX as author discloses a current profitable position.

Buy CLX as a consumer staples play with strong year-to-date performance.

Buy CLX as a defensive consumer staples name showing a technical breakout.

Despite a tough North American market with categories declining, Colgate saw a sequential improvement in December versus October and November in terms of category volume declines, and is planning for a 'slow return' rather than a sharp rebound. — The stability in the U.S. consumer packaged goods market may be a leading indicator for competitors; the lack of a strong rebound suggests continued promotional intensity in the first half of 2026.

Kenvue explicitly stated it is losing share in mouthwash because it is not playing strongly enough in the fastest-growing mild alcohol-free segment, a direct signal to competitors with strong offerings in that segment. — This admission provides a clear roadmap for competitors to double down on the alcohol-free oral care segment to entrench their share gains against Listerine.